RxDoctor Payments Data

Michelle Semins, MD

Urology · Pittsburgh, PANPI 1578609277

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Cook Incorporated at 38.7% of the total. Among urology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$30,667in general payments, 2019–2025

Across 89 payments — averaging $344.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cook Incorporated$12K
  • Boston Scientific$7K
  • Travere Therapeutics, Inc.$5K
  • Novo Nordisk Health Care AG$4K
  • Calyxo, Inc.$3K
  • Sumitomo Pharma America, Inc.$205
  • plus $599 from 9 others

What the payments were for

  • Consulting fees$17,09956%
  • Speaking & faculty fees$9,80032%
  • Travel & lodging$3371%
  • Food & beverage$3,43011%
  • Education$10%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,667 in reported general payments places this provider in the 90th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$75,739
Medicare patients
276
Services billed
682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron21$11,616
Potassium Citrate ErPotassium Citrate130$6,898
Methenamine Hippurate16$1,681
Tamsulosin Hcl115$1,297
Chlorthalidone75$893
Estradiol16$873
Cefpodoxime Proxetil16$841
Finasteride42$460
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav53$369
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst24$222
Ciprofloxacin Hcl29$164
Cefdinir15$160
Fluconazole13$95
Cephalexin18$87
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim28$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$64$11,61621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 596 urology providers in Pennsylvania.

Other urology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →